drugset / Trial / NCT01444807

Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

NCT01444807 ↗

RandomizedSingle-groupDouble-blindTreatment

Summary

Evaluate the efficacy and tolerability of sorafenib in RCC patients underwent to metastasectomy

Timeline

Start
2011-12
Primary completion
2017-03
Completion
2022-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg —

Indications